0001209191-23-047125.txt : 20230823
0001209191-23-047125.hdr.sgml : 20230823
20230823193123
ACCESSION NUMBER: 0001209191-23-047125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230821
FILED AS OF DATE: 20230823
DATE AS OF CHANGE: 20230823
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schneyer Mark C.
CENTRAL INDEX KEY: 0001899977
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 231198651
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC.
STREET 2: 12830 EL CAMINO REAL, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-21
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001899977
Schneyer Mark C.
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO
CA
92130
0
1
0
0
EVP, Chief Financial Officer
1
Common Stock
2023-08-21
4
S
0
10000
28.997
D
15682
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $29.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2023.
/s/ Austin D. Kim, Attorney-in-Fact
2023-08-23